VOR Vor Biopharma Inc. Insider Trading

RA Capital sold 630,374 shares (19.7% of holdings) for $10.2M at avg $16.14 vs. current $15.17; 5 consecutive VOR sales in 5 days while stock -71.6% from 52-week high.

RA Capital Management executed 2 separate sales totaling 630,374 shares for $10,174,787.59, reducing holdings from 3,197,619 shares to 2,567,245 shares—a reduction of 19.7% of pre-transaction holdings. The sales occurred at $16.28 and $15.77 on April 17 and April 20, blending to $16.14 per share, slightly above the current price of $15.17. Most significantly, this filing reflects the third and fourth transactions in a 5-day pattern: RA Capital sold on April 9, 10, 13, 14, and 15—before filing this Form 4 on April 17 for the April 17 and April 20 sales. This high-frequency exit pattern occurs while the stock trades 71.6% below its 52-week high of $53.40 and while the company reported a full fiscal year net loss of $812,684,000 against a market cap of $741,016,635.68. The concentration of sales within days of each other, without measurable outcomes yet from the prior 5 trades at this ticker, suggests sustained pressure to liquidate a significant director-level stake during a period of pronounced valuation compression.

RA Capital Management sold 737,989 shares (738.0K) for $11.9M across 3 transactions, reducing stake 18.8% while stock is down 70.8% from 52-week high.

RA Capital Management, a director at Vor Biopharma, executed 3 separate sales totaling 737,989 shares for $11,883,339.89 at a blended average price of $16.10 on April 13–15, 2026, reducing its holdings from 3.94M to 3.20M shares. The timing is noteworthy: the stock currently trades at $15.60, down 70.8% from its 52-week high of $53.40, yet this sale occurred at prices ($16.15, $15.97, $16.01) that remain above current levels. The company is unprofitable with a net loss of $812.7M and a market cap of $762.0M, signaling fundamental weakness. RA Capital's 5 most recent trades at Vor (April 6–10) were all sales, establishing a clear pattern of position reduction in this name over a compressed timeframe. While the insider's cross-ticker track record shows strong prior buy outcomes (+17.2% average 30-day return), that historical strength does not extend to timing of sales at this specific ticker, where no prior measurable outcomes exist yet.

RA Capital Management sold 620,133 shares for $10.2M across 4 sales Apr 8-10, reducing VOR stake 13.6%

RA Capital Management, a director at Vor Biopharma, executed 4 separate sales totaling 620,133 shares for $10,233,811.45 between April 8-10, 2026, at a blended average price of $16.50 per share. The sales reduce the director's holdings from 4,555,741 shares to 3,935,608 shares, a net reduction of 13.6%. These transactions occur in the context of a company trading 71.0% below its 52-week high of $53.40 and at $15.47 current price, while Vor remains unprofitable with a full-year net income of $-812,684,000.00 against a market cap of $755,670,886.88. The timing of these four sales within a tight 3-day window and the substantial dollar volume warrant investor attention, particularly given the company's continued unprofitability and elevated valuation headwinds from the company's severe drawdown from its recent peak.

RA Capital Management sold 849,257 shares (15.7% of position) for $14,518,963.47; stock down 69.5% from 52-week high

RA Capital Management executed 5 separate sales totaling 849,257 shares for $14,518,963.47 between April 2–6, 2026, at prices ranging from $16.51 to $19.06 (blended average $17.10). The reduction of 15.7% from their pre-transaction position of 5,404,998 shares occurs against a backdrop of severe stock deterioration: the current price of $16.27 reflects a 69.5% decline from the 52-week high of $53.40. Vor Biopharma's fundamentals remain challenged, with a net loss of $-812,684,000.00 against a market cap of $794,748,890.08. Across RA Capital's prior insider history (cross-ticker, 5 prior sells), the insider achieved an 80.00% well-timed rate on sells with an average 90-day return of −3.7%, suggesting prior sales preceded stock declines; however, the current timing context—a stock already down two-thirds from peak—offers limited further downside clarity.

RA Capital Management sold 400,408 shares at blended average $25.90, reducing VOR stake 33.9% amid 53.2% decline from 52-week high

RA Capital Management, a director at Vor Biopharma, executed 4 separate sales totaling 400,408 shares for $10,368,938.18 on October 28–30, 2025, at prices ranging from $25.12 to $28.18 per share. This represents a 33.9% reduction of the insider's holdings from 1,180,060 shares to 779,652 shares. The sales occurred as the stock declined 53.2% from its 52-week high of $53.40 and tumbled 48.7% over the prior 30 days. The company is unprofitable with a net loss of $1,573,669,000 in its most recent full fiscal year and has a market cap of $3,167,077,775. The timing context—five prior sales at VOR within the past week (October 20–27)—suggests sustained selling pressure from this director position, though prior same-ticker sales lack measurable 90-day outcome data to evaluate execution quality.

RA Capital director sells 221,166 shares (15.8% of holdings) across 3 trades for $6.2M; stock down 40.2% in 90 days

RA Capital Management, L.P., a director at Vor Biopharma, executed 3 separate sales totaling 221,166 shares for $6,204,863.17 at an average price of $28.06 between October 23–27, 2025, reducing holdings by 15.8%. The sales occur against a deteriorating stock backdrop: VOR is down 40.2% over 90 days and 47.3% from its 52-week high of $53.40, trading near current lows relative to its 52-week range. The company remains unprofitable with a net income of $-1,573,669,000.00 over its most recent full fiscal year. The timing is notable given RA Capital's recent pattern: 5 prior sales at this ticker on or just before October 20–21, 2025, followed immediately by these larger sales, suggesting heightened liquidity activity in a deteriorating stock environment.

RA Capital Management sold 117,050 shares at $29.34 avg for $3.4M on 2025-10-20–21, reducing stake by 7.7% amid -50.4% decline from 52-week high.

RA Capital Management, a director of Vor Biopharma, executed 5 separate sales totaling 117,050 shares for $3,433,992.06 at a blended average price of $29.34, reducing holdings from 1,518,276 to 1,401,226 shares. The timing is notable: the sales occurred at prices ($29.63–$30.12 on 2025-10-20, and $28.11 on 2025-10-21) that stand well above the current price of $26.50, and within weeks after the company's 52-week high of $53.40, from which the stock has fallen 50.4%. The company is unprofitable with a net loss of $1,573,669,000, trading on the basis of biotech pipeline potential rather than current earnings. While the director retained 1.40M shares post-sale, the execution of multiple sales within a two-day window at elevated relative valuations warrants investor attention to whether this reflects internal reassessment of near-term outlook or valuation inflection.

10% owner Reprogrammed Interchange LLC sold 37,533 shares (37.5K) across 4 sales totaling $1,133,103.32 at VOR, reducing stake to 1,166,909 shares.

Reprogrammed Interchange LLC, a 10% owner of Vor Biopharma, executed 4 separate sales totaling 37,533 shares for $1,133,103.32 between 2025-10-17 and 2025-10-21 at prices ranging from $30.05 to $31.00. The company is unprofitable with net income of $-1,573,669,000.00 over its most recent full fiscal year. Stock has declined 33.6% over the past 90 days and is trading 48.0% below its 52-week high of $53.40 at the current price of $27.77, well below the blended sale price of $30.19. The insider retains 1,166,909 shares post-transaction, representing a 3.1% reduction from the 1,204,442 shares held pre-transaction, maintaining substantial ownership concentration.

RA Capital Management sold 464.0K shares of VOR across 16 transactions on 2025-10-15 to 2025-10-17 for $13.7M, reducing stake by 96.8%

RA Capital Management executed 16 separate sales totaling 464,025 shares for $13,707,361.09 across three consecutive trading days (October 15–17, 2025), reducing its holdings from 479,129 shares to 15,104 shares—a 96.8% reduction. The blended average sale price was $29.54 per share, while the stock currently trades at $29.00, reflecting an adverse -4.6% movement in the 30-day window and a -34.4% decline over 90 days. Notably, VOR remains significantly depressed, trading -45.7% below its 52-week high of $53.40 and the company is unprofitable with a net loss of $-1,573,669,000 over its most recent full fiscal year. RA Capital's cross-ticker track record shows a 75% win rate on 90-day post-purchase returns averaging +13.3%, but the substantial liquidation of a once-material position during a period of steep stock decline and persistent fundamental losses signals a material reduction in directional exposure to VOR.

10% owner Reprogrammed Interchange LLC sold 73,676 shares (73.7K) for $2.3M at blended avg $31.88 as VOR stock down 45.7% from 52-week high.

Reprogrammed Interchange LLC, a 10% shareholder, executed four separate sales totaling 73,676 shares for $2,348,744.16 over two trading days (October 15–16, 2025), reducing holdings by 5.8% to 1,204,442 shares. The sales occurred at prices ranging from $30.45 to $32.77, with a blended average of $31.88, while the current stock price is $29.00—indicating the insider sold above recent market levels. The timing is notable: VOR's stock has fallen 45.7% from its 52-week high of $53.40 and is down 34.4% over the 90-day period, yet the company reported a net loss of $1,573,669,000 over its most recent full fiscal year. The insider's recent selling pattern at this ticker shows five prior transactions within the last few days (October 13–17), suggesting heightened liquidation activity. This concentrated divestiture by a significant shareholder warrants scrutiny given the company's unprofitability and the sharp equity decline, though the absence of scheduled trading plan disclosures prevents determination of whether sales were discretionary or automated.